Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Neutral 0

Cardinal Health Was Supposed to Beat UnitedHealth. Did It? Will It?

📉 The original recommendation favoring Cardinal Health over UnitedHealth was proven incorrect as UnitedHealth significantly outperformed Cardinal in the trailing 12 months.

💰 UnitedHealth returned 35.2% between May 2025 and May 2026, while Cardinal Health returned 21.8% during the same period.

📊 UnitedHealth's strong recent performance was driven by a Q1 2026 EPS beat of $7.23 versus the $6.61 consensus estimate.

⚖️ Cardinal Health delivered a Q3 FY26 non-GAAP EPS beat but suffered from a revenue miss and a significant goodwill impairment charge.

📉 Short-term momentum has shifted against Cardinal, which is down 10.7% over the past month despite missing on key growth metrics.

💡 Analyst consensus for UnitedHealth suggests less upside potential at $387.27 compared to its current share price, reflecting a completed rebound.

🔼 Analyst sentiment favors Cardinal Health with a Wall Street target of $245.27 and an 88% bullish rating distribution from coverage.

📈 Cardinal Health has raised its full-year 2026 EPS guidance to between $10.70 and $10.80, representing 30% to 31% growth.

🧘‍♂️ UnitedHealth's turnaround under CEO Stephen Hemsley has been validated by improved medical cost ratios and stronger operational metrics.

⚠️ Long-term concerns persist for UnitedHealth regarding a DOJ probe and a decline in Medicare Advantage membership of 965,000 members.

🛡️ Cardinal Health offers higher beta with lower volatility (0.54), making it potentially attractive for investors seeking near-term drawdown tolerance.

💵 UnitedHealth generated substantial dividend income by paying $2.0 billion in Q1 2026 alone, appealing to retirement-focused investors.

🎯 Risk-adjusted analysis currently favors Cardinal Health due to wider implied upside and faster growth guidance despite UnitedHealth's strong recent rally.

🔄 The article concludes that the investment decision now splits based on investor profile, with UnitedHealth suited for scale and dividends.

Bullish Signals
  • Cardinal Health delivered strong total returns of 21.8% over the past year, growing from $153.00 to $186.35.
  • Following a Q3 FY26 non-GAAP EPS beat of $3.17 against estimates of $2.79, management has raised full-year guidance to reflect 30% to 31% growth in non-GAAP EPS.
  • The Wall Street consensus price target of $245.27 implies material upside for the stock.
  • Analyst sentiment remains robust with 88% bullish coverage, consisting of three Strong Buy ratings and twelve Buy ratings versus zero Sells.
  • With a beta of 0.54, Cardinal Health offers lower volatility compared to peers while maintaining exposure to healthcare growth.
  • The stock is currently trading below the analyst consensus target, providing room for price appreciation toward $231.18 according to 24/7 Factor targets.
Risk Factors
  • UnitedHealth Group's stock price has nearly doubled since May 29, 2025, leaving very little room for further appreciation as the current share price is already above Wall Street consensus targets.
  • UnitedHealth faces significant overhangs from ongoing Department of Justice Medicare actions and a recent decline in its Medicare Advantage membership of 965,000 members.
  • The stock has rallied significantly, eating up much of the cushion for investors who were previously buying on value or waiting for a better entry point.
  • UnitedHealth's Q1 FY2026 adjusted EPS of $7.23 beat consensus estimates, which is often interpreted by markets as limited upside potential once strong results are priced in.
  • Cardinal Health recently reported a 30.27% year-over-year operating income decline and took an $184 million goodwill impairment related to Navista and ION.
Full Analysis
The article evaluates Cardinal Health (CAH) and UnitedHealth Group (UNH) over a 12-month period starting May 29, 2025, comparing their performance against an earlier prediction that favored Cardinal Health. Although Cardinal Health was the initial recommendation, UnitedHealth outperformed in terms of total return, rising from $296.80 to $401.16 for a gain of 35.2% by May 11, 2026, compared to Cardinal Health's 21.8% return which moved from $153.00 to $186.35. The analysis attributes UnitedHealth's stronger recent performance to its recovery under CEO Stephen Hemsley, noting a significant 27.0% gain in the past month driven by a Q1 2026 adjusted earnings beat where actual results of $7.23 exceeded the consensus estimate of $6.61. Recent financial data highlights divergent paths for the two healthcare giants; UnitedHealth improved its medical cost ratio by 90 basis points to 83.9%, while Cardinal Health faced a market downturn despite a non-GAAP earnings beat in Q3 FY26. The issues impacting Cardinal Health included a 2.09% revenue miss, a 30.27% year-over-year decline in operating income, and a $184 million goodwill impairment related to Navista and ION, leading to a 6.6% decline year-to-date. In contrast, UnitedHealth's upside potential has been partially consumed by its rally, though it remains supported by strong cash generation with $2.0 billion in dividends paid out alone in Q1 2026. Looking forward, the article notes that Cardinal Health currently offers a more bullish analyst outlook than UnitedHealth, which trades above its consensus target price. Wall Street analysts project a consensus target for Cardinal Health of $245.27, implying substantial upside, alongside an 88% bullish rating distribution. Management at Cardinal has raised full-year FY26 non-GAAP earnings guidance to between $10.70 and $10.80, representing 30% to 31% growth. Conversely, UnitedHealth carries lingering risks such as Department of Justice inquiries regarding Medicare and a decline in its member count for Medicare Advantage plans, which keeps the stock trading near its consensus target despite a still-positive 82% analyst sentiment. The summary concludes that investment choice depends on the investor's profile and risk tolerance; UnitedHealth is positioned for retirement portfolios seeking stable dividends and proven turnaround results with lower volatility relative to the sector, whereas Cardinal Health suits investors with a longer horizon seeking higher upside potential based on wider analyst price targets and faster projected earnings growth. The article suggests that on a risk-adjusted basis, Cardinal Health currently presents a favorable setup given UnitedHealth has completed much of its rebound while Cardinal retains significant growth potential ahead.